Zevra Therapeutics prices genetic disorder drug at up to $106,000 per month

Zevra Therapeutics

23/09/2024 13:28

Sept 23 (Reuters) - Zevra Therapeutics'  ZVRA.O  drug,
Miplyffa, for treating a rare and fatal genetic disorder will
have a wholesale acquisition cost ranging between $40,000 and
$106,000 per month depending on dosage, the company said on a
conference call on Monday.
    The U.S. health regulator on Friday approved the drug making
it the first treatment to get a nod for Neimann-Pick disease
type C - a rare genetic condition that affects the nervous
system and other organs.

 (Reporting by Kashish Tandon and Sriparna Roy in Bengaluru;
Editing by Shailesh Kuber)
 ((Kashish.Tandon@thomsonreuters.com; 8800437922;))